Business
ABL Diagnostics Expands HIV Sequencing Expertise into TB Drug Resistance Profiling with New NGS Solutions
WOIPPY, FRANCE, March 20, 2026 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), an innovative company specialized in microbiology and pathogen
About this update from Abl Diagnostics Sa
[{"type":"text","content":"WOIPPY, FRANCE, March 20, 2026 /EINPresswire.com/ -- ABL Diagnostics (FR001400AHX6 – “ABLD”), an innovative company specialized in microbiology and pathogen sequencing, today announced major advancements in its Mycobacterium tuberculosis (MTB) portfolio, combining its current CE-IVD marked DeepChek® Assay 13‑Plex KB and BacterioChek software with the development of new research next‑generation sequencing (NGS) solutions for comprehensive drug resistance detection and genomic surveillance. At the core of its current offering, ABL Diagnostics commercializes the CE-IVD marked DeepChek® Assay 13-Plex KB Drug Susceptibility Testing assay, a multiplex PCR solution enabling the detection of key resistance-associated mutations across first- and second-line anti-TB drugs. Designed for use with NGS workflows, the assay supports amplification of MTB DNA directly from clinical specimens and provides actionable genotyping data to guide treatment decisions. This solution is complemented by BacterioChek, ABL Diagnostics’ CE-IVD software for automated analysis and interpretation of MTB Next-Generation Sequencing data, delivering standardized and clinically relevant reports to support laboratories and clinicians. Building on this integrated workflow, ABL Diagnostics has developed two new solutions intended for research use for now: - A 19-gene resistance panel, expanding coverage beyond the current DeepChek® Assay 13-Plex but with the same input DNA extraction and using the same PCR cycling program, ensuring seamless adoption for existing users. This panel already covers the full set of genes known to be associated with resistance to currently prescribed anti-tuberculosis drugs. These include first and second line treatments such as rifampicin (rpoB), isoniazid (katG, inhA), ethambutol (embB), pyrazinamide (pncA), fluoroquinolones (gyrA, gyrB), aminoglycosides such as amikacin and kanamycin (rrs, eis), as well as newer and repurposed drugs like linezolid (rplC, rrl) and bedaquiline (atpE, Rv0678). By integrating an expanded set of resistance‑associated genes, the 19‑gene panel delivers broader and more informative insights into MTB drug resistance profiles, supporting ongoing research on emerging therapeutic targets and contributing to the development of next‑generation strategies for improved disease management. - A whole genome MTB solution (~...